Mibampator

Mibampator (also known as LY451395) is an Ampakine compound developed by Eli Lilly and Company for potential use in the treatment of Alzheimer's disease and cognitive disorders. It is a positive allosteric modulator of the AMPA receptor, which is involved in synaptic transmission in the brain.

History

Mibampator was first synthesized and developed by Eli Lilly and Company, a global pharmaceutical company. The compound was part of a larger research effort into Ampakines, a class of compounds that enhance the function of the AMPA receptor.

Mechanism of Action

Mibampator works by enhancing the function of the AMPA receptor, a type of ionotropic glutamate receptor that mediates fast synaptic transmission in the brain. It is a positive allosteric modulator, meaning it binds to a site on the receptor different from the active site and enhances the receptor's response to its ligand, glutamate. This is thought to enhance cognitive function and potentially slow the progression of neurodegenerative diseases like Alzheimer's disease.

Clinical Trials

Mibampator has undergone several clinical trials to assess its safety and efficacy in treating cognitive disorders. In Phase II trials, it was found to be safe and well-tolerated, but did not show significant improvement in cognitive function in patients with mild to moderate Alzheimer's disease. Further research is needed to fully understand the potential therapeutic benefits of Mibampator.

See Also

• Ampakine
• AMPA receptor
• Alzheimer's disease
• Cognitive disorders
• Eli Lilly and Company

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

• 
  Mibampator